PCV13 Tied To Modest Additional Protection Against SARS-CoV-2 Among Adults Who Received At Least Two COVID-19 Vaccine Doses, Findings Show

Infectious Disease Advisor (9/12, Basilio) says, “The 13-valent pneumococcal conjugate vaccine (PCV13) is associated with modest additional protection against SARS-CoV-2 infection among adults who have received at least 2 doses of the COVID-19 vaccine, especially those expected to have weaker immune responses to SARS-VoV-2 infection,” researchers concluded in a “retrospective longitudinal cohort study.” The findings were published in the Journal of Infectious Diseases.